Cover Image
市場調查報告書

全球和中國的幹細胞產業報告

Global and China Stem Cell Industry Report, 2015-2018

出版商 ResearchInChina 商品編碼 312752
出版日期 內容資訊 英文 120 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球和中國的幹細胞產業報告 Global and China Stem Cell Industry Report, 2015-2018
出版日期: 2015年11月30日 內容資訊: 英文 120 Pages
簡介

幹細胞是未分化的生物細胞,為了分化為特殊化的細胞,製作更許多幹細胞(透過有絲分裂),可進行分割。幹細胞療法,適應心血管疾病,白血病(血液學系疾病之一),神經系統疾病,肝臟病變,腎臟等病變的治療。

本報告提供全球和中國的幹細胞產業調查分析、概要、產業鏈、上游/中游/下游企業等相關的系統性資訊。

第1章 幹細胞產業概要

  • 定義
  • 分類、應用
  • 產業鏈
  • 開發方針

第2章 全球幹細胞產業鏈

  • 主要企業的產業鏈設計
  • 政策
  • 發展
  • 上游
  • 下游
  • 預測

第3章 中國的幹細胞產業鏈

  • 發展概要
  • 政策環境
  • 上游
  • 中游
  • 下游

第4章 上游企業

  • 簡介、經營、收益結構等
    • Cryo-Cell International
    • Esperite
    • VCANBIO
    • Golden Meditech
    • LifeCell International
    • Cryosite
    • Health & Biotech
    • Tian Qing Stem Cell

第5章 中游、下游企業

  • 簡介、經營、收益結構等
    • Caladrius Biosciences
    • Mesoblast
    • MEDIPOST
    • Beike Biotechnology
    • Osiris Therapeutics
    • Orthofix International
    • Cytori Therapeutics
    • Athersys
    • Pluristem Therapeutics
    • StemCells
    • Ocata
    • Celgene
    • Vitro Biopharma
    • Reneuron
    • Tigenix
    • Cellular Biomedicine
    • SALIAI
    • Opexa Therapeutics
    • ZhongKe Biopharm
    • Cyagen Biosciences

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: ZYM071

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hundreds of diseases in clinical studies, of which about 50% is applied to blood diseases. In addition to blood diseases, tumors, neurological system diseases, heart disease, immune system diseases and the like are also important fields of stem cell clinical research.

Up to now, only 12 sorts of stem cell products have been approved for marketing after rigorous safety and effectiveness review worldwide. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. allowance funds) and the capital support of key partners, very few companies have dropped out.

Considerable stem cell therapy products are in clinical trials worldwide. For example, the United States National Institutes of Health (NIH) had registered 4,293 cord blood-related clinical research projects as of December 23, 2014 and 5,190 ones as of November 17, 2015, including 484 ones in East Asia.

Restricted by policies, capital, technology and other factors, China's stem cell therapy develops slowly. At present, China has not approved any stem cell drug product for marketing. As for stem cell research, Chinese authorities have not accepted or reviewed any stem cell therapy of any medical institution except hematopoietic stem cells suitable for treating blood diseases; besides, the stem cell clinical applications of some hospitals pertain to the scope of pilot clinical studies.

In February 2015, Ministry of Science and Technology of the People's Republic of China published the Stem Cell and Translational Medicine Implementation Plan of National Key R&D Program (Draft). In August 2015, CFDA (China Food and Drug Administration) issued Management on Clinical Stem Cell Experimental Study (Trial). With the relaxation of policies, the stem cell industry has attracted Chinese investors once again.

On December 4, 2014, Xi'an International Medical Investment (formerly known as Kaiyuan Investment) announced to invest RMB270 million in acquiring 34% stake in H & B's registered capital in order to accelerate the development of health care services and foster new profit engines.

On April 17, 2015, Yinhe Investment proclaimed that it would associate with its controlling shareholder Yinhe Group to jointly lavish RMB2 billion in the establishment of Biomedical M&A Fund whose total size hits RMB6 billion. The fund is mainly used for immunotherapy, stem cell clinical application platforms, macromolecular drugs, antibody drug development and other fields.

On October 27, 2015, Ningxia Xinri Hengli Steel Wire Rope Co., Ltd. released a restructuring plan to take over 80% stake in BoyaLife from Xu Xiaochun, , Maoxing Investment Management (Hangzhou), Yang Lijuan , Wang Jianrong, etc. with RMB1.5656 billion.

Global and China Stem Cell Industry Report, 2015-2018 highlights the followings:

  • Classification, application, industry chain definition, etc. of stem cells;
  • Major enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry;
  • Policies, upstream/midstream/downstream development, etc. of China stem cell industry;
  • Operation, stem cell business, etc. of 8 upstream companies and 20 midstream/downstream companies worldwide.

Table of Contents

1. Overview of Stem Cell Industry

  • 1.1 Definition
  • 1.2 Classification and Application
  • 1.3 Industry Chain
  • 1.4 Development Course

2. Global Stem Cell Industry Chain

  • 2.1 Industry Chain Layout of Major Enterprises
  • 2.2 Policy
  • 2.3 Development
  • 2.4 Upstream
  • 2.5 Downstream
  • 2.6 Prospect

3. China Stem Cell Industry Chain

  • 3.1 Development
  • 3.2 Policy
  • 3.3 Upstream
  • 3.4 Midstream
  • 3.5 Downstream

4. Upstream Enterprises

  • 4.1 Cryo-Cell International
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Cord Blood Business
  • 4.2 Esperite
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Stem Cell Business
  • 4.3 VCANBIO
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D and Investment
    • 4.3.6 Stem Cell Business
    • 4.3.7 Development Forecast
  • 4.4 Golden Meditech
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Cord Blood Business
    • 4.4.5 Development Forecast
  • 4.5 LifeCell International
    • 4.5.1 Profile
    • 4.5.2 Cord Blood Business
  • 4.6 Cryosite
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Stem Cell Business
  • 4.7 Health & Biotech
    • 4.7.1 Profile
    • 4.7.2 Operation
  • 4.8 Tian Qing Stem Cell
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure

5. Midstream and Downstream Enterprises

  • 5.1 Caladrius Biosciences
    • 5.1.1 Profile
    • 5.1.2 Operation
    • 5.1.3 Revenue Structure
    • 5.1.4 R&D and Investment
    • 5.1.5 Stem Cell Business
  • 5.2 Mesoblast
    • 5.2.1 Profile
    • 5.2.2 Operation
    • 5.2.3 R&D and Investment
    • 5.2.4 Stem Cell Business
  • 5.3 MEDIPOST
    • 5.3.1 Profile
    • 5.3.2 Operation
    • 5.3.3 Stem Cell Business
  • 5.4 Beike Biotechnology
    • 5.4.1 Profile
    • 5.4.2 Stem Cell Business
  • 5.5 Osiris Therapeutics
    • 5.5.1 Profile
    • 5.5.2 Operation
    • 5.5.3 R&D
  • 5.6 Orthofix International
    • 5.6.1 Profile
    • 5.6.2 Operation
    • 5.6.3 Revenue Structure
    • 5.6.4 R&D
    • 5.6.5 Stem Cell Business
  • 5.7 Cytori Therapeutics
    • 5.7.1 Profile
    • 5.7.2 Operation
    • 5.7.3 R&D
  • 5.8 Athersys
    • 5.8.1 Profile
    • 5.8.2 Operation
    • 5.8.3 R&D
  • 5.9 Pluristem Therapeutics
    • 5.9.1 Profile
    • 5.9.2 R&D and Recent News
  • 5.10 StemCells
    • 5.10.1 Profile
    • 5.10.2 Operation
    • 5.10.3 R&D
  • 5.11 Ocata
    • 5.11.1 Profile
    • 5.11.2 Operation
    • 5.11.3 R&D
  • 5.12 Celgene
    • 5.12.1 Profile
    • 5.12.2 Operation
    • 5.12.3 R&D
  • 5.13 Vitro Biopharma
    • 5.13.1 Profile
    • 5.13.2 Operation
    • 5.13.3 R&D
    • 5.13.4 Stem Cell Business
  • 5.14 Reneuron
    • 5.14.1 Profile
    • 5.14.2 Operation
    • 5.14.3 R&D
  • 5.15 Tigenix
    • 5.15.1 Profile
    • 5.15.2 Operation
    • 5.15.3 R&D
  • 5.16 Cellular Biomedicine
    • 5.16.1 Profile
    • 5.16.2 Operation
    • 5.16.3 R&D
    • 5.16.4 Stem Cell Business
    • 5.16.5 Business in China
  • 5.17 SALIAI
    • 5.17.1 Profile
    • 5.17.2 Operation
    • 5.17.3 Stem Cell Business
  • 5.18 Opexa Therapeutics
  • 5.19 ZhongKe Biopharm
  • 5.20 Cyagen Biosciences

Selected Charts

  • Classification of Stem Cell
  • Overview of Stem Cell Therapy Area (by Disease Type)
  • Advantages and Disadvantages of Stem Cell Therapy
  • Source and Application of Adult Stem Cells (by Type)
  • Stem Cell Industry Chain
  • Industry Chain Distribution of Major Global Stem Cell Enterprises
  • Policy Tendency of Human Embryonic Stem Cell Research Worldwide
  • Stem Cell Products Granted "Orphan Drug" by EU EMEA
  • Global Authorized Stem Cell Varieties
  • Top 20 Indications of Global In-research Stem Cell by the end of 2014
  • Global Stem Cell Products in Late R&D Stage
  • Global Stem Cell Market Size and YoY Growth, 2007-2014
  • Global Human Stem Cell Clinical Trials and Treatment Application Structure, 2014
  • Distribution of Cord Blood-related Research Projects Registered in the US National Institutes of Health, by Nov 17, 2015
  • Clinical Application of Global Stem Cell Technology (by Disease Type), 2014
  • Cord Blood Bank Distribution in Major Countries by the end of 2014
  • Cord Blood Application in Major Countries
  • Global Top 10 Death Causes (by Death Toll), 2012
  • Global Top 10 Death Causes (by Income Group), 2012
  • Global Top 10 Death Causes in Low-income Countries, 2012
  • Global Top 10 Death Causes in Low- and Middle-income Countries, 2012
  • Global Top 10 Death Causes in Middle- and High-income Countries, 2012
  • Global Top 10 Death Causes in High-income Countries, 2012
  • Application Prospect of Global Stem Cell
  • Global Stem Cell Market Size and YoY Growth, 2014-2018E
  • Some Chinese Stem Cell Clinical Trial Drugs Approved by CFDA
  • Construction of Chinese Stem Cell Industrialization Bases
  • China's Stem Cell Industry Policies, 1999-2015
  • Major Enterprises and Their Stem Cell Business in China Upstream Stem Cell Industry
  • Major Enterprises and Their Stem Cell Business in China Midstream Stem Cell Industry
  • Chinese Stem Cell Medical Market Size and YoY Growth, 2007-2018E
  • Revenue and Net Income of Cryo-Cell International, FY2010-FY2015
  • Total Assets, Total Liabilities and Asset-liability Ratio of Cryo-Cell International, FY2010-FY2014
  • Cord Blood Revenue and % of Total Revenue of Cryo-Cell International, FY2012-FY2015
  • Revenue and Net Income of Esperite, 2010-2015
  • Revenue of Esperite (by Business), 2010-2015
  • Revenue Structure of Esperite (by Region), 2014
  • Stem Cell Storage of Esperite, 2009-2014
  • Stem Cell Storage Revenue and EBITA of Esperite, 2010-2015
  • Operation of Main Subsidiaries of VCANBIO by 2015H1
  • Revenue and Net Income of VCANBIO, 2010-2015
  • Revenue of VCANBIO (by Business), 2011-2015
  • Revenue of VCANBIO (by Region), 2011-2015
  • Gross Margin of VCANBIO (by Business), 2011-2015
  • R&D Costs and % of Total Revenue of VCANBIO, 2011-2015
  • Fund-raising Investment Projects and Progress of VCANBIO, by Jun 30, 2015
  • Stem Cell Storage Business of VCANBIO (by Type), 2009-2014
  • Revenue and Net Income of VCANBIO, 2014-2017E
  • Revenue and Net Income of Golden Meditech, FY2009-FY2014
  • Revenue of Golden Meditech (by Business), FY2009-FY2014
  • Cord Blood Bank Revenue and % of Total Revenue of Golden Meditech, FY2011-FY2014
  • Cord Blood Bank Gross Profit and Gross Margin of Golden Meditech, FY2011-FY2014
  • Development Course of Golden Meditech's Cord Blood Storage Business
  • Revenue and Net Income of Golden Meditech, FY2014-FY2018E
  • Development Course of LifeCell International
  • Revenue and Net Income of Cryosite, FY2011-FY2015
  • Revenue and EBITDA of Cryosite (by Business), FY2011-FY2014
  • Equity Structure of Health & Biotech
  • Industry Base Distribution of Health & Biotech
  • Revenue and Net Income of Health & Biotech, 2012-2014
  • Revenue and Net Income of Tian Qing Stem Cell, 2013-2015
  • Revenue (by Business) of Tian Qing Stem Cell, 2013-2015
  • Subsidiaries of Caladrius Biosciences, by the end of 2014
  • Revenue and Net Income of Caladrius Biosciences, 2009-2015
  • Revenue (by Business) of Caladrius Biosciences, 2012-2015
  • R&D Costs and % of Total Revenue of Caladrius Biosciences, 2009-2014
  • M & A Course of Caladrius Biosciences, 2009-2014
  • Revenue and Net Income of Mesoblast, FY2009-FY2015
  • R&D Costs and % of Total Revenue of Mesoblast, FY2009-FY2015
  • M&A Course of Mesoblast by the end of 2014
  • Stem Cell Product R&D Progress of Mesoblast by the end of June 2015
  • Revenue and Net Income of MEDIPOST, 2011-2014
  • Adult Stem Cell Drugs and Therapeutic Area of MEDIPOST
  • Development Course of Beike Biotechnology
  • Stem Cell Brands and Therapeutic Area of Osiris Therapeutics
  • Revenue, Net Income and Gross Margin of Osiris Therapeutics, 2011-2015
  • R&D Costs and % of Total Revenue of Osiris Therapeutics, 2011-2015
  • Revenue, Net Income and Gross Margin of Orthofix International, 2009-2014
  • Revenue of Orthofix International (by Department), 2011-2015
  • R&D Costs and % of Total Revenue of Orthofix International, 2011-2015
  • Revenue, Net Income and Gross Margin of Cytori Therapeutics, 2010-2015
  • Revenue of Cytori Therapeutics (by Region), 2010-2015
  • R&D Costs and % of Total Revenue of Cytori Therapeutics, 2010-2015 Revenue and Net Income of Athersys, 2010-2015
  • Revenue of Athersys (by Source), 2010-2015
  • R&D Costs and % of Total Revenue of Athersys, 2010-2015
  • Significant Cooperative Partners and Areas of Athersys
  • Revenue and Net Income of StemCells, 2011-2015
  • R&D Costs and % of Total Revenue of StemCells, 2011-2015
  • Stem Cell Product R&D, Therapeutic Area and Progress of StemCells by 2015H1
  • Revenue, Net Income and Gross Margin of Ocata, 2010-2015
  • R&D Costs and % of Total Revenue of Ocata, 2010-2015
  • Stem Cell Product R&D, Therapeutic Area and Progress of Ocata by the end of 2014
  • Revenue, Net Income and Operating Margin of Celgene, 2009-2014
  • Cellular Therapy R&D Costs and % of Total Revenue of Celgene, 2009-2013
  • Stem Cell Products R&D, Therapeutic Area and Progress of Celgene as of 2014H1
  • Revenue and Net Income of Vitro Biopharma, FY2009-FY2015
  • R&D Costs and % of Total Revenue of Vitro Biopharmas, FY2009-FY2015
  • Stem Cell Brands and Application Fields of Vitro Biopharma
  • Revenue and Net Income of Reneuron, FY2010-FY2015
  • R&D Costs and % of Total Revenue of Reneuron, FY2010-FY2015
  • Stem Cell Products R&D, Therapeutic Area and Progress of Reneuron by the end of 2014
  • Revenue and Net Income of Tigenix, 2009-2015
  • Sales of Tigenix (by Region), 2011-2013
  • R&D Costs and % of Total Revenue of Tigenix, 2012-2015
  • Stem Cell Product R&D, Therapeutic Area and Progress of Tigenix by 2015H1
  • Development Course of Cellular Biomedicine
  • Revenue and Net Income of Cellular Biomedicine, 2013-2015
  • R&D Costs and % of Total Revenue of Cellular Biomedicine, 2013-2015
  • Stem Cell Product R&D, Therapeutic Area and Progress of Cellular Biomedicine by 2015H1
  • Revenue and Net Income of SALIAI, 2013-2015

Related Companies

  • Zhongyuan Union Stem Cell Bioengineering Co., Ltd.(600645.SH)
Back to Top